Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Bethesda, Maryland 20892.
Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Bethesda, Maryland 20892.
J Biol Chem. 2013 Jun 7;288(23):16895-16904. doi: 10.1074/jbc.M112.434217. Epub 2013 Apr 23.
Activating mutations in the αC-β4 loop of the ERBB2 kinase domain, such as ERBB2(YVMA) and ERBB2(G776VC), have been identified in human lung cancers and found to drive tumor formation. Here we observe that the docking protein GAB1 is hyper-phosphorylated in carcinomas from transgenic mice and in cell lines expressing these ERBB2 cancer mutants. Using dominant negative GAB1 mutants lacking canonical tyrosine residues for SHP2 and PI3K interactions or lentiviral shRNA that targets GAB1, we demonstrate that GAB1 phosphorylation is required for ERBB2 mutant-induced cell signaling, cell transformation, and tumorigenesis. An enzyme kinetic analysis comparing ERBB2(YVMA) to wild type using physiologically relevant peptide substrates reveals that ERBB2(YVMA) kinase adopts a striking preference for GAB1 phosphorylation sites as evidenced by ∼150-fold increases in the specificity constants (kcat/Km) for several GAB1 peptides, and this change in substrate selectivity was predominantly attributed to the peptide binding affinities as reflected by the apparent Km values. Furthermore, we demonstrate that ERBB2(YVMA) phosphorylates GAB1 protein ∼70-fold faster than wild type ERBB2 in vitro. Notably, the mutation does not significantly alter the Km for ATP or sensitivity to lapatinib, suggesting that, unlike EGFR lung cancer mutants, the ATP binding cleft of the kinase is not significantly changed. Taken together, our results indicate that the acquired substrate preference for GAB1 is critical for the ERBB2 mutant-induced oncogenesis.
在人类肺癌中已发现 ERBB2 激酶结构域的αC-β4 环中的激活突变,例如 ERBB2(YVMA)和 ERBB2(G776VC),并且发现这些突变可驱动肿瘤形成。在这里,我们观察到,在转基因小鼠的癌组织中和表达这些 ERBB2 癌突变体的细胞系中,衔接蛋白 GAB1 被过度磷酸化。使用缺乏 SHP2 和 PI3K 相互作用的典型酪氨酸残基的显性负 GAB1 突变体或针对 GAB1 的慢病毒 shRNA,我们证明 GAB1 磷酸化是 ERBB2 突变体诱导的细胞信号传导、细胞转化和肿瘤发生所必需的。使用生理相关的肽底物对 ERBB2(YVMA)与野生型进行的酶动力学分析表明,与野生型 ERBB2 相比,ERBB2(YVMA)激酶对 GAB1 磷酸化位点具有惊人的偏好性,这表现为几种 GAB1 肽的特异性常数 (kcat/Km) 增加了约 150 倍,这种底物选择性的改变主要归因于肽结合亲和力,如表观 Km 值所反映的那样。此外,我们证明 ERBB2(YVMA)在体外比野生型 ERBB2 对 GAB1 蛋白的磷酸化速度快约 70 倍。值得注意的是,该突变并未显著改变 Km 值对于 ATP 或对拉帕替尼的敏感性,这表明与 EGFR 肺癌突变体不同,激酶的 ATP 结合裂隙没有明显改变。总之,我们的结果表明,对 GAB1 的获得性底物偏好对于 ERBB2 突变体诱导的致癌作用至关重要。